Restricted accessResearch articleFirst published online 2016-11
Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens,Menopause,and Response to Therapy Trials
Conjugated estrogens/bazedoxifene (CE/BZA) reduced menopause-related hot flashes (HFs) in the Selective estrogens, Menopause, And Response to Therapy (SMART) trials. This post hoc pooled analysis of SMART-1 and -2 further characterized effects of CE/BZA on HFs in the overall population and patient subgroups.
Methods:
Data from two randomized, double-blind, placebo- and active-controlled, phase 3 studies were pooled for nonhysterectomized postmenopausal women with moderate/severe HFs given CE 0.45 mg/BZA 20 mg, CE 0.625 mg/BZA 20 mg, or placebo for 12 weeks. HF frequency and severity were assessed by daily diary.
Results:
The pooled analysis included 403 participants. At 12 weeks, CE 0.45 mg/BZA 20 mg and CE 0.625 mg/BZA 20 mg significantly (all p < 0.001) decreased moderate/severe HF frequency versus placebo (−7.9, −8.2, −4.1), reduced adjusted average daily HF severity score versus placebo (−1.0, −1.3, −0.3), increased the percentage of women who had a ≥50% (81.2%,87.1%, 50.6%) and ≥75% (62.4%, 74.8%, 26.4%) reduction from baseline in daily frequency of moderate/severe HFs, increased the percentage with ≥50% (38.3%, 58.1%, 11.0%) and ≥75% (24.2%, 38.1%, 5.5%) reductions in average daily HF severity score, and improved MENQOL vasomotor function versus placebo (adjusted mean change–3.08, −3.69, −1.37). CE/BZA was significantly more effective than placebo irrespective of time since menopause, with some evidence of a lower placebo response in women in later menopause (>5 years) versus early menopause (≤5 years).
Conclusions:
CE/BZA effectively reduces moderate/severe HFs in postmenopausal women.
NCT#'s: NCT00675688; NCT00234819
Get full access to this article
View all access options for this article.
References
1.
DennersteinL, DudleyEC, HopperJL, GuthrieJR, BurgerHG. A prospective population-based study of menopausal symptoms. Obstet Gynecol, 2000; 96:351–358.
2.
Mac BrideMB, RhodesDJ, ShusterLT. Vulvovaginal atrophy. Mayo Clin Proc, 2010; 85:87–94.
3.
The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause, 2010; 17:25–54.
4.
UtianWH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review. Health Qual Life Outcomes, 2005; 3:47.
5.
WilliamsRE, KalilaniL, DiBenedettiDB, ZhouX, FehnelSE, ClarkRV. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas, 2007; 58:348–358.
6.
The North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause, 2012; 19:257–271.
7.
BarnabeiVM, CochraneBB, AragakiAK, et al.Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol, 2005; 105:1063–1073.
8.
MansonJE, ChlebowskiRT, StefanickML, et al.Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 2013; 310:1353–1368.
9.
KharodeY, BodinePV, MillerCP, LyttleCR, KommBS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology, 2008; 149:6084–6091.
10.
KommBS. A new approach to menopausal therapy: The tissue selective estrogen complex. Reprod Sci, 2008; 15:984–992.
11.
KommBS, MirkinS. The tissue selective estrogen complex: A promising new menopausal therapy. Pharmaceuticals (Basel), 2012; 5:899–924.
12.
MirkinS, PinkertonJV, KaganR, et al.Gynecologic safety of conjugated estrogens plus bazedoxifene: Pooled analysis of five phase 3 trials. J Womens Health (Larchmt), 2016; 25:431–442.
13.
Duavee [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc., A subsidiary of Pfizer, Inc., 2015.
14.
Duavive [summary of product characteristics]. London, United Kingdom: European Medicines Agency, 2014.
15.
PickarJH, YehIT, BachmannG, SperoffL. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril, 2009; 92:1018–1024.
16.
LoboRA, PinkertonJV, GassML, et al.Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril, 2009; 92:1025–1038.
17.
ArcherDF, LewisV, CarrBR, OlivierS, PickarJH. Bazedoxifene/conjugated estrogens (BZA/CE): Incidence of uterine bleeding in postmenopausal women. Fertil Steril, 2009; 92:1039–1044.
18.
LindsayR, GallagherJC, KaganR, PickarJH, ConstantineG. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril, 2009; 92:1045–1052.
19.
HarveyJA, PinkertonJV, BaracatEC, ShiH, ChinesAA, MirkinS. Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. Menopause, 2013; 20:138–145.
20.
PinkertonJV, UtianWH, ConstantineGD, OlivierS, PickarJH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: A randomized, controlled trial. Menopause, 2009; 16:1116–1124.
21.
UtianW, YuH, BobulaJ, MirkinS, OlivierS, PickarJH. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas, 2009; 63:329–335.
22.
KaganR, WilliamsRS, PanK, MirkinS, PickarJH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause, 2010; 17:281–289.
23.
BachmannG, BobulaJ, MirkinS. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric, 2010; 13:132–140.
24.
MirkinS, KommBS, PanK, ChinesAA. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric, 2013; 16:338–346.
25.
PinkertonJV, HarveyJA, PanK, et al.Breast effects of bazedoxifene-conjugated estrogens: A randomized controlled trial. Obstet Gynecol, 2013; 121:959–968.
26.
PinkertonJV, PanK, AbrahamL, et al.Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: A randomized trial. Menopause, 2014; 21:252–259.
27.
PinkertonJV, HarveyJA, LindsayR, et al.Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: A randomized trial. J Clin Endocrinol Metab, 2014; 99:E189–E198.
28.
HilditchJR, LewisJ, PeterA, et al.A menopause-specific quality of life questionnaire: Development and psychometric properties. Maturitas, 1996; 24:161–175.
29.
WyrwichKW, SprattDI, GassM, YuH, BobulaJD. Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause, 2008; 15:698–705.
30.
Food and Drug Administration, Center for Drug Evaluation and Research. Application number 022247Orig1 s000: Summary Review for Regulatory Action. October2013. Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022247Orig1s000SumR.pdf Accessed January20, 2016.
31.
AbrahamL, BushmakinAG, DragonE, KommBS, PinkertonJV. Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women [abstract]. Presented at the Congress of the European Menopause and Andropause Society; May20–22, 2015; Madrid, Spain.
32.
WilliamsRE, KalilaniL, DiBenedettiDB, et al.Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric, 2008; 11:32–43.
33.
MacLennanAH, BroadbentJL, LesterS, MooreV. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev, 2004:CD002978.
34.
ArcherDF. Endometrial bleeding in postmenopausal women: With and without hormone therapy. Menopause, 2011; 18:416–420.
35.
ReganMM, EmondSK, AttardoMJ, ParkerRA, GreenspanSL. Why do older women discontinue hormone replacement therapy?. J Womens Health Gend Based Med, 2001; 10:343–350.
36.
CrandallCJ, AragakiAK, CauleyJA, et al.Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. Breast Cancer Res Treat, 2012; 131:969–979.
37.
CrandallCJ, AragakiAK, CauleyJA, et al.Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone Women's Health Initiative clinical trials. Breast Cancer Res Treat, 2012; 132:275–285.
38.
PinkertonJV, AbrahamL, BushmakinAG, et al.Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective Estrogens, Menopause and Response to Therapy (SMART) Trials. J Womens Health (Larchmt), 2014; 23:18–28.
